Clinical trial
Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma
NCT00002748 · St. Jude Children's Research Hospital, Other · Completed
Key facts
| NCT number | NCT00002748 |
|---|---|
| Title | Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma |
| Official title | Phase I Study of Cytokine-Gene Modified Autologous or Partially Matched Allogeneic Neuroblastoma Cells for Treatment of Relapsed/Refractory Neuroblastoma |
| Lead sponsor | St. Jude Children's Research Hospital, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological |
| Interventions | gene-modified tumor cell vaccine therapy, interleukin-2 gene |
| Enrollment | 38 |
| Start date | Dec 1, 1991 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jan 22, 2004 |
| Last update posted | Oct 4, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: